I3Y-MC-JPCM: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506777-36-00

Acronym

I3Y-MC-JPCM

Enrollment

Registered

2024-02-19

Start date

2019-01-04

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Radiographic Progression Free Survival (rPFS)

Interventions

DRUGPREDNISOLONE

DRUGVerzenios 50 mg film-coated tablets

DRUGPlacebo to match LY2835219 (Abemaciclib) Tablets

DRUGPlacebo to match LY2835219 (Abemaciclib) Capsules

DRUGPREDNISONE

DRUGABIRATERONE

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Radiographic Progression Free Survival (rPFS)	—

Countries

Denmark, France, Germany, Netherlands, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026

I3Y-MC-JPCM: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer